new cancer therapies with novel mechanisms and functions are needed to treat patients with different cancers. virotherapy is a good scenario for such treatment. the advantages of virotherapy include the potential lack of cross resistance with standard therapies and the ability to cause tumor destruction by numerous mechanisms. oncolytic virus not only possesses unique mechanisms of action that ...

Oncolytic virotherapy (OV) is a cancer therapy utilizing lytic viruses that specifically target cells for elimination. In this relatively new therapy, two contradictory observations have been made. Some studies showed immune responses including activated natural killer (NK) post oncolytic viral infection increased the cell death, while others reported such initial diminished anti-tumor efficacy...

Head and neck cancer (HNC) is the sixth most common malignancy worldwide. Despite recent advancements in surgical, chemotherapy, and radiation treatments, HNC remains a highly morbid and fatal disease. Unlike many other cancers, local control rather than systemic control is important for HNC survival. Therefore, novel local therapy in addition to systemic therapy is urgently needed. Oncolytic v...

The last few years have seen an increased interest in immunotherapy in the treatment of malignant disease. In particular, there has been significant enthusiasm for oncolytic virotherapy, with a large amount of pre-clinical data showing promise in animal models in a wide range of tumour types. How do we move forward into the clinical setting and translate something which has such potential into ...

abstract :  reovirus (respiratory enteric orphan virus), a naturally occurring benign human pathogen, has an inherent ability to target transformed and cancerous cells and cause their lysis, while leaving non-transformed cells relatively unaffected.  the efficiency of this innate oncolytic activity of reovirus correlates with expression of the ras oncogene.  cells expressing activated ras and t...

adenocarcinoma (PDAC) remains a highly lethal disease with a median survival time that does not exceed 6.5 months [1]. Since more than 80% of patients present with advanced metastatic disease, systemic chemotherapy remains the only treatment. The high resistance to conventional and targeted therapies in PDAC as in other desmoplastic tumors of adults is largely due to the dense extracellular mat...

Summary Cancer therapeutics can lead to immune equilibrium in which the response controls tumor cell expansion without fully eliminating cancer. The factors involved this remain incompletely understood, especially those that would antagonize anti-tumor and outgrowth. We previously demonstrated continuous treatment with a non-replicating herpes simplex virus 1 expressing interleukin (IL)-12 indu...